Jonathan Albert Rose, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 3 | 2023 | 808 | 1.110 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2023 | 451 | 0.750 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 2019 | 246 | 0.710 |
Why?
|
| Hypertension, Pulmonary | 4 | 2023 | 1537 | 0.700 |
Why?
|
| Pulmonary Fibrosis | 1 | 2023 | 530 | 0.650 |
Why?
|
| Hemangioblasts | 1 | 2014 | 28 | 0.500 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 168 | 0.490 |
Why?
|
| Leukocytes | 2 | 2018 | 2043 | 0.400 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 977 | 0.390 |
Why?
|
| Enzyme Inhibitors | 3 | 2015 | 3798 | 0.340 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 3047 | 0.310 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 1351 | 0.300 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 2046 | 0.270 |
Why?
|
| Hematopoiesis | 1 | 2014 | 2072 | 0.260 |
Why?
|
| Escherichia coli | 2 | 2015 | 4217 | 0.230 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 4456 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 7181 | 0.200 |
Why?
|
| Endothelial Cells | 1 | 2014 | 3479 | 0.200 |
Why?
|
| Flow Cytometry | 3 | 2018 | 5974 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 13102 | 0.200 |
Why?
|
| Lung | 4 | 2023 | 9856 | 0.190 |
Why?
|
| Scleroderma, Systemic | 1 | 2023 | 323 | 0.170 |
Why?
|
| Alprenolol | 1 | 2016 | 8 | 0.140 |
Why?
|
| Fibrosis | 1 | 2023 | 2029 | 0.130 |
Why?
|
| Epoprostenol | 1 | 2016 | 254 | 0.130 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2016 | 264 | 0.130 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 459 | 0.120 |
Why?
|
| Azepines | 1 | 2015 | 336 | 0.110 |
Why?
|
| Crystallography, X-Ray | 2 | 2015 | 2011 | 0.110 |
Why?
|
| Connective Tissue Diseases | 1 | 2016 | 264 | 0.110 |
Why?
|
| DNA Topoisomerase IV | 1 | 2012 | 41 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2012 | 87 | 0.100 |
Why?
|
| Haemophilus influenzae | 1 | 2012 | 171 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3129 | 0.100 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 664 | 0.100 |
Why?
|
| Oxygen | 1 | 2023 | 4189 | 0.100 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2012 | 371 | 0.090 |
Why?
|
| Drug Design | 1 | 2015 | 1076 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2015 | 3701 | 0.080 |
Why?
|
| Disease Progression | 2 | 2023 | 13284 | 0.080 |
Why?
|
| Firearms | 1 | 2015 | 598 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2015 | 5456 | 0.080 |
Why?
|
| Gene Expression | 2 | 2023 | 7799 | 0.070 |
Why?
|
| Smoking | 1 | 2023 | 8987 | 0.070 |
Why?
|
| Cell Lineage | 1 | 2014 | 2504 | 0.070 |
Why?
|
| Humans | 13 | 2023 | 744343 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2014 | 2948 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2014 | 4026 | 0.060 |
Why?
|
| Indoles | 1 | 2012 | 1839 | 0.060 |
Why?
|
| Uridine Triphosphate | 1 | 2023 | 26 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 3508 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12245 | 0.050 |
Why?
|
| Dementia | 1 | 2015 | 2518 | 0.050 |
Why?
|
| Cytokines | 1 | 2014 | 7322 | 0.040 |
Why?
|
| Isoproterenol | 1 | 2019 | 399 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.040 |
Why?
|
| Age Factors | 1 | 2016 | 18370 | 0.040 |
Why?
|
| Phenotype | 1 | 2016 | 16365 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2023 | 867 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2014 | 11483 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2018 | 241 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2012 | 1375 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 9239 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2012 | 1877 | 0.030 |
Why?
|
| Middle Aged | 4 | 2023 | 213383 | 0.030 |
Why?
|
| Male | 6 | 2023 | 350118 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2012 | 1035 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 8863 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 1240 | 0.030 |
Why?
|
| Aza Compounds | 1 | 2012 | 32 | 0.030 |
Why?
|
| Female | 5 | 2023 | 380194 | 0.030 |
Why?
|
| DNA Gyrase | 1 | 2012 | 83 | 0.030 |
Why?
|
| Rifampin | 1 | 2012 | 315 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2012 | 500 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1770 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 63114 | 0.020 |
Why?
|
| Adult | 3 | 2023 | 214055 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2012 | 839 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2023 | 7729 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 163280 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 944 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2023 | 4468 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 687 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2015 | 1329 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 3846 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 19905 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2012 | 4011 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 6114 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8642 | 0.010 |
Why?
|
| Algorithms | 1 | 2023 | 13881 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2023 | 77449 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9386 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 3848 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 20947 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23403 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 57776 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 29786 | 0.000 |
Why?
|
| Animals | 1 | 2019 | 168757 | 0.000 |
Why?
|